Alcidion Group Limited (ALC) AI Stock Analysis

• Market Cap: AU$154.44M
• Dividend Yield: N/A
• Average Volume (3M): 796.98K
• Price to Earnings (P/E): 95.8
• Beta (1Y): 1.09
• Revenue Growth: 10.06%
• EPS Growth: N/A
• Country: AU
• Employees: 145
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): <0.01
• Shares Outstanding: 1,342,952,600
• 10 Day Avg. Volume: 536,053
• 30 Day Avg. Volume: 796,979
• PEG Ratio: -0.70
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 3.38
• P/FCF Ratio: 24.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.15
• Price Target Upside: 46.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: AU$0.13 ▲(30.00% Upside)

The score is driven mainly by improving financial performance (strong revenue growth, very low leverage, and sharply better cash generation) and supportive technical trend signals (price above key moving averages with positive MACD). These positives are moderated by an expensive valuation (P/E 108.33) and still-weak operating profitability (negative EBIT margin and low net margin).

Positive Factors

Recurring revenue model and partnerships

A subscription-based, cloud software model creates predictable, recurring revenue and higher customer stickiness. Strategic partnerships with healthcare organizations broaden the sales pipeline and drive long-term adoption, supporting durable revenue visibility and lower churn risk.

High gross margin and solid top-line growth

Very high gross margins reflect a scalable software business with low incremental delivery costs, allowing operating leverage as revenue scales. Combined with mid-teens revenue growth, this supports sustainable margin expansion potential if fixed operating costs are managed.

Strong cash generation and very low leverage

A dramatic improvement in free cash flow and minimal debt gives the company financial flexibility to invest in R&D, sales expansion or M&A without pressure from creditors. This durable balance-sheet strength reduces solvency risk through economic cycles.

Negative Factors

Low net profitability

A single-digit net margin limits retained earnings and reduces capacity to self-fund growth or return capital to shareholders. Persistently low profitability can constrain investment in product development and sales, slowing long-term competitive progress.

Negative EBIT margin indicates operational gaps

A negative EBIT margin shows core operations are not yet consistently profitable before interest and taxes, pointing to structural cost or scaling inefficiencies. Without improved operating efficiency or higher scale, sustaining competitive investment may pressure margins long term.

Limited organizational scale

A relatively small headcount can limit capacity for large-scale deployments, global expansion, and 24/7 customer support common in health systems. Scaling operations will require sustained hiring and training, increasing fixed costs and execution risk over the medium term.

Alcidion Group Limited Business Overview & Revenue Model

Company Description

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.

How the Company Makes Money

Alcidion Group Limited generates revenue primarily through the sale of software licenses, subscriptions, and related services to healthcare providers. The company offers a recurring revenue model through annual subscriptions for its cloud-based solutions, providing a steady income stream. Key revenue streams also include implementation services, training, and support services provided to clients post-sale. Additionally, Alcidion has formed strategic partnerships with various healthcare organizations and technology firms, which enhance its market presence and can lead to new business opportunities. Factors contributing to its earnings include the increasing demand for digital health solutions, particularly in response to the challenges faced by healthcare systems globally, and ongoing investments in product development to maintain competitiveness in the evolving health tech landscape.

Alcidion Group Limited Financial Statement Overview

Summary

Solid fundamentals supported by strong revenue growth (14.45%), very high gross margin (88.24%), and exceptionally improved free cash flow growth (3584.97%) with strong FCF-to-net income (0.98). Offsetting this, profitability remains thin (net margin 4.06%) and EBIT margin is negative, indicating ongoing operating challenges.

Income Statement

Alcidion Group Limited has shown a positive revenue growth rate of 14.45% in the latest year, indicating a strong upward trajectory. The gross profit margin is high at 88.24%, reflecting efficient cost management. However, the net profit margin is relatively low at 4.06%, suggesting limited profitability. The EBIT margin is negative, indicating operational challenges, but the EBITDA margin is positive, showing some improvement in operational efficiency.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.016, indicating strong financial stability and low leverage risk. The return on equity is modest at 1.88%, suggesting limited profitability from shareholders' investments. The equity ratio is not provided, but the overall balance sheet reflects a stable financial position with low debt levels.

Cash Flow

Alcidion Group Limited has demonstrated a significant improvement in free cash flow growth, with a remarkable increase of 3584.97%. The operating cash flow to net income ratio is 0.28, indicating a healthy conversion of income into cash. The free cash flow to net income ratio is high at 0.98, showing strong cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.79M	40.79M	37.06M	40.40M	34.35M	25.88M
Gross Profit	35.99M	35.99M	31.92M	1.25M	3.29M	3.52M
EBITDA	1.94M	1.94M	-4.50M	-1.43M	-1.58M	-474.00K
Net Income	1.65M	1.65M	-8.42M	-3.62M	-4.41M	-2.24M
Balance Sheet
Total Assets	115.63M	115.63M	114.46M	120.68M	128.35M	58.38M
Cash, Cash Equivalents and Short-Term Investments	17.70M	17.70M	11.80M	14.64M	17.34M	25.03M
Total Debt	1.41M	1.41M	1.70M	2.15M	2.48M	181.00K
Total Liabilities	27.82M	27.82M	27.52M	30.52M	34.40M	13.16M
Stockholders Equity	87.80M	87.80M	86.94M	90.17M	93.95M	45.22M
Cash Flow
Free Cash Flow	5.64M	5.64M	-7.18M	-285.00K	685.00K	1.23M
Operating Cash Flow	5.76M	5.76M	-7.13M	169.00K	996.00K	1.54M
Investing Cash Flow	-125.00K	-125.00K	-53.00K	-3.14M	-59.74M	-9.84M
Financing Cash Flow	-764.00K	-764.00K	4.34M	-616.00K	51.33M	17.23M

Alcidion Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.11, and above the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.41 is Neutral, neither overbought nor oversold. The STOCH value of 31.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	67 Neutral	AU$154.44M	95.83	1.89%	―	10.06%	―
ONE	54 Neutral	AU$270.99M	-10.86	―	―	21.56%	-24.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMT	51 Neutral	AU$58.12M	-8.45	-13.83%	―	3.61%	-17.03%
M7T	48 Neutral	AU$97.53M	-16.09	-12.35%	―	15.99%	22.05%
SHG	43 Neutral	AU$77.34M	-10.79	―	―	―	―
PCK	42 Neutral	AU$53.30M	-5.95	-8647.54%	―	25.98%	22.10%

Alcidion Group Limited Corporate Events

Alcidion Expands Contract Pipeline and Reaffirms Guidance on Strong Q2 Momentum

Alcidion reported solid momentum in the December quarter of FY26, highlighted by its selection as preferred supplier for a major Electronic Patient Record contract with University Hospitals Sussex NHS Foundation Trust, expected to carry a total contract value of at least $35 million and become its largest UK engagement once executed. Quarterly new total contract value reached $15.4 million, driven largely by a $12.3 million expansion of its Miya Precision deployment with Leidos for the Commonwealth of Australia and several renewals, lifting FY26 contracted revenue to $43.1 million as at 31 December—40% higher than a year earlier and already exceeding FY25 full-year revenue. Despite an operating cash outflow of $1.9 million in Q2, the company ended the period with $14.2 million in cash, no debt, a sizeable debtor ledger and strong January collections, and it reaffirmed guidance for positive EBITDA and operating cash flow at least in line with FY25, underscoring improving scale, disciplined cost management and growing recurring revenue for stakeholders.

The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Schedules Q2 FY26 Cash Flow Release and Investor Webcast

Alcidion Group Limited will release its Appendix 4C Quarterly Cash Flow Report for the quarter ended 31 December 2025 (Q2 FY26) on 15 January 2026 and will host a live investor webcast the same day, led by Group Managing Director and CEO Kate Quirke and CFO Matthew Gepp. The webcast will cover operational and commercial highlights for the quarter and include a Q&A session, signalling the company’s ongoing engagement with investors as it continues to scale its healthcare technology footprint across key markets.

The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Named Preferred EPR Supplier for Major UK NHS Trust

Alcidion Group has been selected as the preferred supplier of a new Electronic Patient Record (EPR) system for University Hospitals Sussex NHS Foundation Trust in the UK, following a competitive tender process. The trust, one of the country’s largest acute providers with seven hospitals and nearly 20,000 staff, already uses Alcidion’s Patientrack solution and will expand this relationship through deployment of the Miya Precision platform, including Miya Observations and Assessments, to deliver real-time access to patient records, streamline patient flow and enhance clinical decision-making. The total contract value is under negotiation but is expected to exceed A$35 million over at least seven years, with deployment targeted to commence in the fourth quarter of FY26, underscoring Alcidion’s strengthening foothold in the UK healthcare market and reinforcing its position as a key digital health partner for large NHS trusts.

The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Expands Contract with Leidos Australia, Boosting Revenue and Market Position

Alcidion Group Limited has expanded its contract with Leidos Australia to enhance the use of its Miya Precision software, securing a total contract value of $12.3 million until June 2028. This expansion is expected to add $2.5 million to Alcidion’s annual recurring revenue, with significant revenue recognition projected for FY26, aligning with a larger contract that could extend to 2036, thus strengthening Alcidion’s market position in healthcare technology.

The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.